In Wuhan Healthgen Biotechnology Corp. v. U.S. ITC, the Federal Circuit upheld an ITC ruling that Ventria Bioscience met the domestic industry requirement despite a modest investment in a patented biotech product.
In Wuhan Healthgen Biotechnology Corp. v. U.S. ITC, the Federal Circuit upheld an ITC ruling that Ventria Bioscience met the domestic industry requirement despite a modest investment in a patented biotech product.
